Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
Condo3e
Condo3e Jul. 14 at 6:31 PM
$BCLI just remember: I not here for the dental plan. Peter Pitts on joining Brainstorm Board of Directors
1 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 6:12 PM
$BCLI Our goose is cooked.
1 · Reply
Condo3e
Condo3e Jul. 14 at 5:19 PM
$BCLI Plenty of shareholder value here, why else would Peter Pitts join the board.
1 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 4:36 PM
$BCLI Management is missing and hiding.
0 · Reply
Mobagri
Mobagri Jul. 14 at 3:41 PM
$BCLI piece of shit management Fraud company
1 · Reply
afc2881
afc2881 Jul. 14 at 3:26 PM
$BCLI This is a total 💩 show. No communication what so ever. Total disregard for keeping shareholders & pals abrest of what is going on! Is there anybody in there????
2 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 3:06 PM
$BCLI Where is management?
0 · Reply
afc2881
afc2881 Jul. 14 at 2:01 PM
$BCLI Chaim are u still there??? Any confirmation would be great......
0 · Reply
Condo3e
Condo3e Jul. 13 at 9:10 PM
$BCLI Management Has Gone Silent
2 · Reply
Condo3e
Condo3e Jul. 13 at 8:31 PM
$BCLI Bottom Line — Why the exosome platform is where the value is Because it is: ✔ the real mechanism ✔ the FDA‑aligned part ✔ the partner‑ready part✔ the scalable part ✔ the spinoff‑ready part ✔ the acquisition‑worthy part ✔ the part INSPECT can validate ✔ the part Big Pharma actually wants NurOwn’s future value is not in the cells. It’s in the exosomes the cells produce — and the new ability to analyze them at single‑particle resolution. That’s the asset.
1 · Reply
Latest News on BCLI
No data available.
Condo3e
Condo3e Jul. 14 at 6:31 PM
$BCLI just remember: I not here for the dental plan. Peter Pitts on joining Brainstorm Board of Directors
1 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 6:12 PM
$BCLI Our goose is cooked.
1 · Reply
Condo3e
Condo3e Jul. 14 at 5:19 PM
$BCLI Plenty of shareholder value here, why else would Peter Pitts join the board.
1 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 4:36 PM
$BCLI Management is missing and hiding.
0 · Reply
Mobagri
Mobagri Jul. 14 at 3:41 PM
$BCLI piece of shit management Fraud company
1 · Reply
afc2881
afc2881 Jul. 14 at 3:26 PM
$BCLI This is a total 💩 show. No communication what so ever. Total disregard for keeping shareholders & pals abrest of what is going on! Is there anybody in there????
2 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 14 at 3:06 PM
$BCLI Where is management?
0 · Reply
afc2881
afc2881 Jul. 14 at 2:01 PM
$BCLI Chaim are u still there??? Any confirmation would be great......
0 · Reply
Condo3e
Condo3e Jul. 13 at 9:10 PM
$BCLI Management Has Gone Silent
2 · Reply
Condo3e
Condo3e Jul. 13 at 8:31 PM
$BCLI Bottom Line — Why the exosome platform is where the value is Because it is: ✔ the real mechanism ✔ the FDA‑aligned part ✔ the partner‑ready part✔ the scalable part ✔ the spinoff‑ready part ✔ the acquisition‑worthy part ✔ the part INSPECT can validate ✔ the part Big Pharma actually wants NurOwn’s future value is not in the cells. It’s in the exosomes the cells produce — and the new ability to analyze them at single‑particle resolution. That’s the asset.
1 · Reply
Condo3e
Condo3e Jul. 13 at 8:23 PM
$BCLI BrainStorm’s exosome technology is where the value is because it is the only part of the company that aligns with where the science, the FDA, and Big Pharma are all moving right now.
1 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 13 at 3:20 PM
$BCLI Enough talk time to walk the walk. Enough talk about exosomes and this other bs. None of that matters. Only thing that matters is getting funding and getting the trial started.
2 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 13 at 3:14 PM
$BCLI Share price back below a $1 and heading in the wrong direction. We need and deserve an update from management.
0 · Reply
Condo3e
Condo3e Jul. 12 at 9:49 PM
$BCLI A. NurOwn’s mechanism is exosome‑driven — but poorly characterized FDA has repeatedly said: NurOwn’s mechanism is unclear exosome payloads are not well defined batch consistency is insufficient biomarkers are missing Shih’s lab specializes in solving these exact problems.
1 · Reply
Condo3e
Condo3e Jul. 12 at 9:47 PM
$BCLI Dr. Wei‑Chuan Shih’s lab is strategically relevant to BrainStorm because it provides the nanophotonic, single‑exosome analytical capabilities that NurOwn has always lacked — and that FDA has always demanded.
0 · Reply
afc2881
afc2881 Jul. 12 at 12:44 AM
$BCLI Condo, that is an incredible find. Now all we need is for Fda to give the nod pals been waiting for. Lets go fda.
0 · Reply
Condo3e
Condo3e Jul. 12 at 12:41 AM
$BCLI INSPECT — the technology described in your tab (turn0browsertab1145978244) — is a major scientific tailwind for BrainStorm because it: solves FDA’s biggest concerns clarifies NurOwn’s mechanism enables exosome biomarkers strengthens CMC consistency increases platform value enables partnerships enables a spinoff enables a multi‑billion‑dollar acquisition This is the first time in years that the science and the regulatory strategy finally align.
1 · Reply
Condo3e
Condo3e Jul. 12 at 12:29 AM
$BCLI "To address such an unmet need, we are developing an Integrated Nanophotonic Imaging and Spectroscopy Technology (INSPECT) for scalable, multi-parametric single exosome analysis," said Shih.
2 · Reply
Condo3e
Condo3e Jul. 11 at 8:31 PM
$BCLI Advanced imaging technology unlocks exosome potential for disease diagnosis. https://www.news-medical.net/news/20260701/Advanced-imaging-technology-unlocks-exosome-potential-for-disease-diagnosis.aspx
0 · Reply
Condo3e
Condo3e Jul. 11 at 8:25 PM
$BCLI **BrainStorm’s exosome platform is realistically worth: $400M – $900M today** based on current science, clinical data, and pharma interest.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jul. 10 at 1:46 PM
$BCLI Yep Doctor I don't need to now since it is working now. LOL
0 · Reply
DoctorJT
DoctorJT Jul. 10 at 6:21 AM
$BCLI I think @ALSCellTherapy is now forgetting to post the daily price action. I wonder why?
0 · Reply